Pharmacielo Ltd V.PCLO

PharmaCielo Announces Strategic Partnership with CANNPRISMA

[Betteryear2]

• Will bring unique high-THC Colombian strains owned by PharmaCielo to Europe for the first time.
   
• Combines PharmaCielo's expertise in producing premium medicinal cannabis products, with CANNPRISMA's conversion capabilities, to bring patients in Europe the highest quality high-THC flower product currently available in the market.

Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - April 19, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has partnered with CANNPRISMA - PHARMA, LDA ("CANNPRISMA"), a Portuguese Contract Manufacturing Organization ("CMO"), to supply high-quality EU-GMP1 certified medicinal cannabis flower to the European market. PharmaCielo will provide GACP2 flower to CANNPRISMA, which will convert the flower to EU-GMP standards and distribute it directly from Portugal to European customers. CANNPRISMA is a Portuguese medical cannabis company founded in 2018 that encompasses all aspects of the production process, from cultivation to distribution and research. The company's main objective is to provide high-quality medicinal cannabis products that comply with GACP and GMP standards, and serve as a reference in the market, ultimately contributing to enhancing the quality of life for as many people as possible.

PharmaCielo Announces Strategic Partnership with CANNPRISMA to Supply EU-GMP Certified Dried Flower to the European Medicinal Cannabis Market (newsfilecorp.com)